Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Year-End Submission Rate Stabilizes In 2005 As NDA Approvals Drop

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The slow-down in year-end FDA submissions in recent years appears to have stabilized in 2005, with 16 filings in December – up slightly from 13 in December 2004.

You may also be interested in...

Estimated FDA User Fee Review Goals For Pending NDAs/BLAs


Replidyne Orapem Antibiotic Likely To Need Additional Trials Before Approval

Replidyne is conducting an additional Phase III trial of its oral beta-lactam antibiotic Orapem in anticipation of an FDA request for additional studies, according to the firm’s initial public offering prospectus.

Allergan Highlights Botox, Retina Programs; Overactive Bladder Next Botox Claim?

Allergan and partner Sirna hope to advance novel RNAi-based retinal disease agent Sirna-027 into Phase II trials for macular degeneration this year, according to Allergan

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts